Key result
Improved FMD and baPWV after OMT are linked to ~75% fewer cardiovascular events in CAD.
Why the study?
To examine whether improvement in brachial FMD and baPWV provides an additive cardiovascular risk reduction beyond achieving optimal goals of traditional risk factors in CAD patients.
Does improvement in FMD and baPWV predict reduced cardiovascular events in patients with CAD on optimal medical treatment?
Cohort (n=323)
No
Does improvement in FMD and baPWV predict reduced cardiovascular events in patients with CAD on optimal medical treatment?
Effect estimate: HR 0.25 (95% CI 0.12-0.51)
p-value: p=<0.001
Improvement in both FMD and baPWV after 24 weeks of optimal medical treatment provides additive predictive value for reducing residual cardiovascular risk in patients with CAD.
May refine residual risk stratification in CAD on OMT; leaves open whether targeting FMD/baPWV improves outcomes.
AIM: To examine whether improvement in flow-mediated endothelium-dependent dilatation (FMD) of the brachial artery and brachial-ankle pulse wave velocity (baPWV) has an additive effect on achieving optimal goals of traditional risk factors to reduce cardiovascular risk in patients with coronary artery disease (CAD). METHODS: We assessed 323 patients with CAD and impaired vascular function, defined as an impaired FMD of the brachial artery (<5.5%) and increased baPWV (>1,440 cm/sec). After FMD and baPWV measurements at 24 weeks of optimal medical treatment (OMT), the study patients were followed up for <60 months or until a composite of cardiac death, nonfatal myocardial infarction (MI), unstable angina, or ischemic stroke occurs. RESULTS: During the median follow-up period of 35 months, cardiovascular events occurred in 72 patients. Multivariate Cox hazards analysis showed that patients with an improvement in FMD and baPWV had the lowest probability of future cardiovascular events. In addition, the improvement in FMD and baPWV had a significant incremental effect on the predictive value of the achievement of optimal goals for blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), and hemoglobin A1c (HbA1c) using net reclassification improvement (NRI) and integrated discrimination improvement (IDI). CONCLUSIONS: The improvement in FMD and baPWV had additive effects on risk reduction of the achievement of the optimal goals of traditional risk factors in patients with CAD. Thus, serial measurements of FMD and baPWV may be useful for identifying CAD patients at residual risk for adverse cardiovascular events following OMT.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2020) conducted a cohort in Coronary Artery Disease (n=323). Improvement in both FMD and baPWV vs. No improvement in FMD and baPWV was evaluated on Composite of cardiac death, nonfatal myocardial infarction, unstable angina, or ischemic stroke (HR 0.25, 95% CI 0.12-0.51, p=<0.001). Improvement in both flow-mediated dilation and brachial-ankle pulse wave velocity after optimal medical treatment significantly reduced the risk of cardiovascular events in patients with CAD (HR 0.25).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: